Praxis Precision Medicines (PRAX) officer reports tax share withholding

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. reported an insider tax-withholding transaction by its Principal Accounting Officer, Lauren Mastrocola. On 01/12/2026, 344 shares of common stock were withheld by the company at a price of $275.74 per share to cover tax obligations arising from the vesting of previously reported restricted stock units. After this automatic withholding, Mastrocola directly beneficially owns 13,445.656 shares of Praxis common stock. The filing is a routine Form 4 disclosure of this non-open-market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mastrocola Lauren

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	344	$275.74	$95K

Holdings After Transaction: Common Stock — 13,445.656 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mastrocola Lauren

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		F(1)		344	D	$275.74	13,445.656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Praxis (PRAX) report in this Form 4?

Praxis Precision Medicines, Inc. reported that Principal Accounting Officer Lauren Mastrocola had 344 shares of common stock withheld on 01/12/2026 to cover tax obligations from vesting restricted stock units.

What was the share price used for the Praxis (PRAX) tax withholding?

The company used a price of $275.74 per share when 344 Praxis common shares were withheld to satisfy tax withholding obligations related to restricted stock unit vesting.

How many Praxis (PRAX) shares does the reporting officer own after the transaction?

Following the reported tax-withholding transaction, Principal Accounting Officer Lauren Mastrocola beneficially owns 13,445.656 shares of Praxis Precision Medicines, Inc. common stock directly.

Was this Praxis (PRAX) insider transaction an open-market sale?

No. According to the footnote, the 344 shares were withheld by the issuer to satisfy tax withholding obligations tied to vesting restricted stock units, rather than sold on the open market.

What role does the reporting person hold at Praxis Precision Medicines (PRAX)?

The reporting person, Lauren Mastrocola, is an officer of Praxis Precision Medicines, Inc. with the title Principal Accounting Officer, as indicated in the Form 4.